Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 201–300 of 1,689
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562
“basis of this relationship remains uncertain [99].”
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
“APOE4 is the strongest and most highly replicated risk factor for late-onset sporadic AD [21,27].”
BackgroundVerghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
“7 times, and the presence of two copies increases the risk by about 12 times (9) (www.”
BackgroundOn the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
“As an example of the role of genetic factors, one allele of APOE4 shifts the risk curve for the disease to 5 years earlier, two copies of APOE4 shift it 10 years earlier, and one copy of the APOE2 allele shifts it 5 years later [34, 35].”
BackgroundThe significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
“The e4-allele of the apolipoprotein E gene has been attributed to constitute a major genetic risk factor to develop late-onset Alzheimer’s disease (Corder et al., 1993, 1998; Cruz-Sánchez et al., 2000) and is assumed to affect the cho- linergic deficit.”
BackgroundThe Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
“However, specific risk factors for AD have been recently identified and include aging, the presence of the apolipoprotein E4 (ApoE4) allele [5] and vascular diseases such as stroke and heart disease [6-10].”
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
“…strokes (ischemic and hemorrhagic), raumatic brain injuries (reviewed in Bartzokis et al., 2006a, 007a), as well as age-related neurodegenerative diseases uch as AD, PD, DLB, and amyotrophic lateral sclerosis ALS) (Borroni et al., 2006; Corder et al., 1993; Li et al., 004; Zareparsi et al., 2002).”
Mitochondrial Disorders in the Nervous System
DiMauro, S., & Schon, E. A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094302 · Cited by 536
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Hsiao, K. K., Borchelt, D. R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., Younkin, S., Price, D., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90107-8 · Cited by 523
“Genes on chromosomes 21, 19, 14, and 1 are associated with AD (Goate et al., 1991 ; Corder et al., 1993; LevyLehad et al., 1995; Sherrington et al., 1995).”
Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524
“…allele of the gene encoding apolipoprotein E (apoE) has been linked to late-onset familial and sporadic Alzheimer's disease (AD) and has a gene-dose effect on the risk and age of onset of the disease (Corder et al., 1993; Saunders et al., 1993; Roses, 1996; Tang et al., 1998; Romas et al., 2002).”
BackgroundInfluentialInconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
“Also, the risk allele APOE4 may relate to reduced Aβ clearance from the brain [99].”
BackgroundInfluentialCentral Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism
Mahley, R. W. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307023 · Cited by 516
The neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
“Apolipoprotein E-e4 allele has been classified as one of the important genetic risk factors for late-onset AD and drives the accumulation of parenchymal A plaques.(39) This gene is viewed as a susceptibility gene, in contrast to deterministic genes, such as the APP or presenilin mutations.”
BackgroundThe probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
González, F., Zhu, Z., Shi, Z.-D., Lelli, K., Verma, N., Li, Q. V., & Huangfu, D. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.018 · Cited by 503
“, from 0 to 1 and to 2) is associated with increased risk and decreased onset age (Corder et al., 1993).”
BackgroundSmoking and increased Alzheimer's disease risk: A review of potential mechanisms
Durazzo, T. C., Mattsson, N., Weiner, M. W., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.009 · Cited by 451
“Specifically, the risk for AD doubles every 5 years between the ages of 60 to 90 years [68], AD risk for those with one copy of the APOE ε 4 allele is increased by three to five times, and inheritance of two copies (i.e., APOE ε 4 homozygotes) is associated with a 12-fold increased risk [69].”
Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain
Balin, B. J., Gérard, H. C., Arking, E. J., Appelt, D. M., Branigan, P. J., Abrams, J. T., Whittum-Hudson, J. A., & Hudson, A. P. (1998) · Medical Microbiology and Immunology · doi:10.1007/s004300050071 · Cited by 506
“Not all patients expressing ε4 develop AD, but it has been reported that the allele increases risk for the disease severalfold, and that its presence is associated with earlier onset and more rapid progression in FAD [20, 83].”
BackgroundInfluentialRevisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486
Saunders, A. M., Roses, A. D., Pericak-Vance, M. A., Dole, K. C., Strittmatter, W. J., Schmechel, D. E., Szymanski, M. H., McCown, N., Manwaring, M. G., Schmader, K., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91709-u · Cited by 498
Self-citationAPOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes
Blanchard, J. W., Akay, L. A., Davila-Velderrain, J., von Maydell, D., Mathys, H., Davidson, S. M., Effenberger, A., Chen, C.-Y., Maner-Smith, K., Hajjar, I., et al. (2022) · Nature · doi:10.1038/s41586-022-05439-w · Cited by 496
“The following quality measures were quantified for each cell: (1) the number of genes for which at least one read was mapped (indicative of library complexity); (2) the total number of counts; and (3) the percentage of reads mapped to mitochondrial genes (used to approximate the relative amount of endogenous RNA and c…”
The quest for genetic determinants of human longevity: challenges and insights
Christensen, K., Johnson, T. E., & Vaupel, J. W. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1871 · Cited by 489
“cgi?id=104300">Alzheimer disease , whereas APOE2 is protectiv”
BackgroundResolving controversies on the path to Alzheimer's therapeutics
Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493
“e2/e2 0 1 (7) 1 (2) 0 e2/e3 3 (6) 3 (21) 6 ( 10 ) 5 (16) e2/e4 3 (6) 0 3 (5) 0 e3/e3 16 (35) 9 (64) 25 (42) 22 (69) e3/e4 23 (50)‡ 1 (7) 24 (40) 5 (16) e4/e4 1 (2) 0 1 (2) 0 All 46 (100) 14 (100) 60 (100) 32 (100)”
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
New insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Finch, C. E., & Tanzi, R. E. (1997) · Science · doi:10.1126/science.278.5337.407 · Cited by 492
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
“…protein (APP) genes account for many early-onset AD cases with autosomal dominant inheritance, the apolipoprotein E (APOE) ε4 allele accounts for many cases of late-onset AD (LOAD), with dementia onset after age 60 (Papassotiropoulos et al., 2006; Corder et al., 1993, 1994; Farrer et al., 1997).”
Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury
Nicoll, J. A. R., Roberts, G. W., & Graham, D. I. (1995) · Nature Medicine · doi:10.1038/nm0295-135 · Cited by 486
James, K. A., Stromin, J. I., Steenkamp, N., & Combrinck, M. I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085950 · Cited by 364
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481
“An association was also identified between APOE ε4, a major risk factor for AD [12], and TDP-43.”
BackgroundThe Meningeal Lymphatic System: A New Player in Neurophysiology
Da Mesquita, S., Fu, Z., & Kipnis, J. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.022 · Cited by 479
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
“4 (7-100), n 14 Animal naming fluency (range), number per minute 7.”
BackgroundInfluentialAge-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease
Wang, S.-C., Oelze, B., & Schumacher, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002698 · Cited by 466
“The risk associated with the e4 allele is dose dependent and it was shown previously that the relative APOE e4 mRNA level is increased in AD compared to controls, suggesting that variability in the neuronal expression of APOE contributes to disease risk [19,20].”
BackgroundWhat makes a good genetic association study?
Hattersley, A. T., & McCarthy, M. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67531-9 · Cited by 470
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474
Self-citationThe molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473
Self-citationThe Aging Hippocampus: Cognitive, Biochemical and Structural Findings
Driscoll, I. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg081 · Cited by 448
“Presence of the APOE ε4 allele is a susceptibility gene known to influence age of onset and the underlying pathology of AD (Corder et al., 1993).”
BackgroundModeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471
“have higher levels of tau phosphorylation compared to APOE3 cells [35, 38, 39, 110, 114].”
BackgroundRandom forest-based similarity measures for multi-modal classification of Alzheimer's disease
Gray, K. R., Aljabar, P., Heckemann, R. A., Hammers, A., & Rueckert, D. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.065 · Cited by 456
“The most common is ε 3, while ε 4 is associated with an increased risk of developing AD, and ε 2 with a reduced risk (Corder et al., 1993).”
Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study
Wilson, P. W. F. (1994) · JAMA · doi:10.1001/jama.1994.03520210050031 · Cited by 468
A Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review of the Evidence
Petersson, S. D., & Philippou, E. (2016) · Advances in Nutrition · doi:10.3945/an.116.012138 · Cited by 466
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1485 · Cited by 464
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
“Association of the APOEe4 allele with increased risk and an earlier age of onset of late-onset AD was first reported in 1993 [94,95], while in 1998 the PEREC-1 gene (in 2002 discovered to be the TOMM40 gene) was determined to be associated with the risk of AD [96,97].”
BackgroundBreitner, J. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00049-k · Cited by 466
Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease
van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Hofman, A., & Broeckhoven, C. V. (1994) · Nature Genetics · doi:10.1038/ng0594-74 · Cited by 454
Berchtold, N. C., & Cotman, C. W. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00052-9 · Cited by 430
Deciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Lipoprotein receptors in the nervous system
Herz, J., & Bock, H. H. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135342 · Cited by 457
Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging
Chetelat, G. A., & Baron, J.-C. (2003) · NeuroImage · doi:10.1016/s1053-8119(02)00026-5 · Cited by 444
“…1997); —a family history of AD, which increases the risk of developing AD two-to fivefold (van Duijn and Hofman, 1992); —the E4 allele of apolipoprotein E (Corder et al., 1993): risk for AD increases from 20 to 90% with increasing numbers of APOE-epsilon 4 alleles in families with late onset AD.”
BackgroundThe genetics of sex differences in brain and behavior
Ngun, T. C., Ghahramani, N., Sánchez, F. J., Bocklandt, S., & Vilain, E. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.10.001 · Cited by 440
“Gonadal hormones implicated in genderrelated cognitive deficits of AD but the interaction is complex [145] APOE allele type [146; 147] (i.”
BackgroundElusive roles for reactive astrocytes in neurodegenerative diseases
Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453
“Energy deficits are a common hallmark of various ND (Lin and Beal, 2006), suggesting that some metabolic interactions are altered when astrocytes become reactive in ND.”
BackgroundTrommsdorff, M., Borg, J.-P., Margolis, B., & Herz, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33556 · Cited by 453
ApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
“Hence, APOE4 mutations are a high risk factor that can lead to early onset AD.(12) Although a number of mechanisms have been proposed to link APOE4 to Ab,(13,14) the general consensus is that APOE4 isoform activity increases Ab peptide concentration by decreasing its clearance.”
BackgroundTHE USE OF ANIMAL MODELS TO STUDY THE EFFECTS OF AGING ON COGNITION
Gallagher, M., & Rapp, P. R. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.339 · Cited by 430
Apolipoprotein E and Cognitive Performance: A Meta-Analysis.
Small, B. J., Rosnick, C. B., Fratiglioni, L., & Bäckman, L. (2004) · Psychology and Aging · doi:10.1037/0882-7974.19.4.592 · Cited by 447
Amyloid toxicity in Alzheimer’s disease
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselman, L. J. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0063 · Cited by 447
Alzheimer’s disease pathogenesis and therapeutic interventions
Parihar, M. S., & Hemnani, T. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.12.007 · Cited by 433
Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches
Behl, C. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00055-0 · Cited by 445
Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., D'Angelo, G., Liu, C., Dixit, S., Benzinger, T., Fagan, A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-10.2010 · Cited by 437
“The APOE4 allele, the major genetic susceptibility factor for late-onset AD, present in 15% of the population (Strittmatter and Roses, 1996), confers dramatically increased risk in a gene dosedependent manner for the development of AD with an earlier age of onset (Corder et al., 1993).”
BackgroundThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Sleep-disordered breathing advances cognitive decline in the elderly
Osorio, R. S., Gumb, T., Pirraglia, E., Varga, A. W., Lu, S.-E., Lim, J., Wohlleber, M. E., Ducca, E. L., Koushyk, V., Glodzik, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001566 · Cited by 427
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
(1994) · PubMed Central · Cited by 441
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
“The three main genetic variants of APOE in human confer different risks of developing AD: compared to the most prevalent APOE e3 allele, the e2 allele decreases disease risk by 40%while the e4 allele increases risk by 300% [45,46,123].”
BackgroundChia, R., Sabir, M. S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R. H., Gustavsson, E., Walton, R. L., Ahmed, S., Viollet, C., Ding, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00785-3 · Cited by 438
Fullerton, S. M., Clark, A. G., Weiss, K. M., Nickerson, D. A., Taylor, S. L., Stengård, J. H., Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/303070 · Cited by 432
“It is now recognized that inheritance of e4 alleles increases the risk of AD in a dose-dependent manner and predisposes carriers to an earlier age at onset than matched controls (Corder et al. 1993; Strittmatter et al. 1993).”
BackgroundA new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia
Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21321 · Cited by 421
“A concentrations in the conditioned media were measured by ELISA using Human Amyloid (1-42) (N) and (1-40) (N) kits (IBL, Gunma, Japan).”
MethodStrategies for disease modification in Alzheimer's disease
Citron, M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1495 · Cited by 429
“, and it is intriguing that apolipoprotein E4 (APOE4), the main genetic risk factor for A”
BackgroundCalderón-Garcidueñas, L., Franco-Lira, M., Henríquez-Roldán, C., Osnaya, N., González-Maciel, A., Reynoso-Robles, R., Villarreal-Calderon, R., Herritt, L., Brooks, D., Keefe, S., et al. (2010) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2009.02.117 · Cited by 426
“…e 4 allele is a major genetic risk factor for the development of Alzheimer's disease (AD) and older adult e 4 carriers perform poorly on odor identification tests (Corder et al., 1993; Graves et al., 1999; Kovács, 2004; Calhoun- Haney and Murphy, 2005; Handley et al., 2006; Olofsson et al., 2008).”
BackgroundKuusisto, J., Koivisto, K., Mykkänen, L., Helkala, E.-L., Vanhanen, M., Hänninen, T., Kervinen, K., Kesäniemi, Y. A., Riekkinen, P. J., & Laakso, M. (1997) · BMJ · doi:10.1136/bmj.315.7115.1045 · Cited by 429
Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., et al. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.43 · Cited by 432
“Therefore, it cannot b excluded that this ps-2 mutation is a rare polymorphism not related to AD pathogenesis, since the patient also had an APOE ε3ε4 genotype which may have increased her risk of developing AD (30).”
BackgroundMeningeal lymphatics affect microglia responses and anti-Aβ immunotherapy
Da Mesquita, S., Papadopoulos, Z., Dykstra, T., Brase, L., Farias, F. G., Wall, M., Jiang, H., Kodira, C. D., de Lima, K. A., Herz, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03489-0 · Cited by 431
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
“[24] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.”
BackgroundThe effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis
Wisdom, N. M., Callahan, J. L., & Hawkins, K. A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.003 · Cited by 415
Intelligence: Genetics, Genes, and Genomics.
Plomin, R., & Spinath, F. M. (2004) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.86.1.112 · Cited by 418
“Although the association between allele 4 of APOE and LOAD was reported a decade ago (Corder et al., 1993), it has already become routine in research on dementia to genotype subjects for APOE in order to ascertain whether the results differ for individuals with and without this genetic risk factor.”
ResultSlot, R. E. R., Sikkes, S. A. M., Berkhof, J., Brodaty, H., Buckley, R., Cavedo, E., Dardiotis, E., Guillo‐Benarous, F., Hampel, H., Kochan, N. A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.003 · Cited by 428
“APOE ε4 status was associated with an increased risk of dementia, which appeared to be attributable to the risk of AD but not to non-AD, which is in agreement with the literature [37,38].”
Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0004-z · Cited by 428
“Apolipoprotein (apo) E4, the major genetic risk factor for AD 3,4 , is found to be associated with increases in both pathologies 1 .”
Single nucleotide polymorphisms and the future of genetic epidemiology
Schork, N. J., Fallin, D., & Lanchbury, J. S. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.580402.x · Cited by 412
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Petrella, J. R., Coleman, R. E., & Doraiswamy, P. M. (2003) · Radiology · doi:10.1148/radiol.2262011600 · Cited by 427
“The 3 allele is thought to represent no increased or decreased risk (36).”
BackgroundPerez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426
Olfactory and other sensory impairments in Alzheimer disease
Murphy, C. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0097-5 · Cited by 425
Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.
Smith, M. A., Kutty, R. K., Richey, P. L., Yan, S. D., Stern, D., Chader, G. J., Wiggert, B. O., Petersen, R. B., & Perry, G. L. (1994) · PubMed Central · Cited by 462
Genetic architecture of quantitative traits in mice, flies, and humans
Flint, J., & Mackay, T. F. C. (2009) · Genome Research · doi:10.1101/gr.086660.108 · Cited by 410
“, the identification of the epsilon4 allele of APOE [APOE*4] as a susceptibility gene for Alzheimer’s disease [Corder et al. 1993]), but the majority of genetic studies of human quantitative phenotypes became mired in failures to replicate.”
Jun, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.201 · Cited by 422
“Lateonset AD, the common form of the disease, has been more difficult to solve, with apolipoprotein E (APOE) being the only confirmed susceptibility locus.(5) The combination of high-density genotyping methods, large well-characterized AD and control populations, and statistical methods to evaluate population stratifi…”
Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
Schwarzman, A. L., Gregori, L., Vitek, M. P., Lyubski, S., Strittmatter, W. J., Enghilde, J. J., Bhasin, R., Silverman, J., Weisgraber, K. H., & Coyle, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8368 · Cited by 413
Self-citationRodent models for Alzheimer disease
Götz, J., Bodea, L.-G., & Goedert, M. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0054-8 · Cited by 394
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421
β-Amyloid burden in healthy aging: Regional distribution and cognitive consequences
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., Mathews, D., & Park, D. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318245d295 · Cited by 419
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418
Pascual-Leone, A., Freitas, C., Oberman, L., Horvath, J. C., Halko, M., Eldaief, M., Bashir, S., Vernet, M., Shafi, M., Westover, B., et al. (2011) · Brain Topography · doi:10.1007/s10548-011-0196-8 · Cited by 388
“…genetic polymorphisms on distinct aspects of brain plasticity is the apolipoprotein E (APOE) susceptibility gene located on chromosome 19 and its e4 allele, which is thought to raise the risk of AD (e.g., Corder et al. 1993) in a dose-dependent manner (Bertram et al. 2007; Bertram and Tanzi 2009).”
BackgroundFallin, D., Cohen, A., Essioux, L., Chumakov, I., Blumenfeld, M., Cohen, D., & Schork, N. J. (2001) · Genome Research · doi:10.1101/gr.148401 · Cited by 421
“The association between the APOE 4 allele and late-onset AD has been widely replicated in familial and sporadic samples (Corder et al. 1993; Saunders et al. 1993; Strittmatter et al. 1993; Farrer et al. 1997).”
BackgroundThe age factor in Alzheimer’s disease
Guerreiro, R., & Bras, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0232-5 · Cited by 415
“However, the genes involved in AAO variance mostly remain to be identified; linkage and candidate gene studies have established several possible associations with different loci, but the only consistently replicated modulator of AD AAO, in both familial and sporadic cases, is also the strongest genetic risk locus for…”
BackgroundInfluential
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.